ReNeuron Group Plc (RENE):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ReNeuron Group Plc (RENE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10128
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:59
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ReNeuron Group Plc (ReNeuron) is a clinical-stage stem cell company which develops innovative stem cell therapies targeting areas of significant unmet medical need. The company’s therapeutic candidates in clinical development are focused at treating motor disability as a result of stroke, critical limb ischaemia and the blindness-causing disease retinitis pigmentosa. Its lead CTX stem cell therapeutic candidate is a therapy for treating patients left disabled by a stroke. ReNeuron utilizes its exclusive stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be administered “off-the-shelf” to any fit patient without the requirement for additional immunosuppressive drug treatments. ReNeuron is headquartered in Pencoed, Bridgend, the UK.

ReNeuron Group Plc (RENE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ReNeuron Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ReNeuron Group Plc, Medical Devices Deals, 2012 to YTD 2018 10
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
ReNeuron Enters into Research Agreement with Benitec Biopharma 12
ReNeuron Enters Into Co-Development Agreement With Cell Therapy Catapult 13
Licensing Agreements 14
ReNeuron Enters into Licensing Agreement with US-Based Pharma Company 14
Equity Offering 15
ReNeuron Raises USD105 Million in Private Placement of Shares 15
ReNeuron Raises USD25.4 Million in Private Placement of Shares 16
ReNeuron Group Completes Private Placement Of Shares For US$8.7 Million 17
ReNeuron Group Completes Rights Offering Of Shares For US$1 Million 19
ReNeuron Group Plc – Key Competitors 21
ReNeuron Group Plc – Key Employees 22
ReNeuron Group Plc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Jul 12, 2018: ReNeuron: Preliminary results for the year ended 31 March 2018 24
Dec 14, 2017: ReNeuron Group: Interim Results for the six months ended 30 September 2017 30
Jun 29, 2017: ReNeuron Group: Preliminary Results for the Year Ended 31 March 2017 33
Corporate Communications 34
Apr 10, 2018: ReNeuron: Appointment of US-based Chief Medical Officer 34
Apr 10, 2018: Appointment Of US-Based Chief Medical Officer 35
Sep 01, 2017: ReNeuron Group: Non-executive Director Appointment 36
Jul 19, 2017: ReNeuron Group: Board change 37
Government and Public Interest 38
Apr 19, 2018: ReNeuron: Wins grant for retinal cell therapy development 38
May 11, 2017: ReNeuron awarded major UK cell therapy manufacturing grant 39
Jan 23, 2017: Merck Announces Emerging Biotech Grant Program Winners 40
Product News 41
11/08/2017: ReNeuron Group: Retinal disease clinical trial moves into Phase II 41
06/19/2017: FDA approves cryopreserved formulation of ReNeurons retinal stem cell therapy candidate 42
05/05/2017: ReNeuron presents new data with its exosome therapy programme at major scientific conference 43
04/19/2018: ReNeuron wins grant for retinal cell therapy development 44
Mar 26, 2018: ReNeuron Group: Product Development Update 45
Clinical Trials 47
May 04, 2018: ReNeuron Group: Exosome data presented at ISCT conference 47
Feb 13, 2018: ReNeuron Group: Positive pre-clinical data in nerve injury 48
Jan 26, 2018: ReNeuron: Phase II stroke data presented at AHA conference 49
Dec 14, 2017: ReNeuron Group: Stroke Clinical Trial Regulatory Approval in US 50
Oct 31, 2017: ReNeuron Group: Positive stroke clinical data & regulatory update 51
Oct 09, 2017: ReNeuron presents positive pre-clinical data with its ExoPr0 exosome cancer therapy candidate at American Society for Exosomes and Microvesicles 2017 Annual Meeting 52
Jun 05, 2017: ReNeuron progresses clinical and regulatory strategy for the US with stroke programme based on positive FDA regulatory feedback 53
May 18, 2017: ReNeuron presents positive pre-clinical data with its ExoPr0 exosome therapy candidate at major scientific conference 54
Apr 21, 2017: ReNeuron advances global clinical development strategy with cell therapy candidate for stroke disability 55
Other Significant Developments 56
Sep 19, 2018: ReNeuron Group provides business development update 56
Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 57
Apr 21, 2017: ReNeuron successfully develops cryopreserved formulation of its retinal stem cell therapy candidate and expands ophthalmology programmes 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ReNeuron Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ReNeuron Group Plc, Deals By Therapy Area, 2012 to YTD 2018 9
ReNeuron Group Plc, Medical Devices Deals, 2012 to YTD 2018 10
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ReNeuron Enters into Research Agreement with Benitec Biopharma 12
ReNeuron Enters Into Co-Development Agreement With Cell Therapy Catapult 13
ReNeuron Enters into Licensing Agreement with US-Based Pharma Company 14
ReNeuron Raises USD105 Million in Private Placement of Shares 15
ReNeuron Raises USD25.4 Million in Private Placement of Shares 16
ReNeuron Group Completes Private Placement Of Shares For US$8.7 Million 17
ReNeuron Group Completes Rights Offering Of Shares For US$1 Million 19
ReNeuron Group Plc, Key Competitors 21
ReNeuron Group Plc, Key Employees 22
ReNeuron Group Plc, Subsidiaries 23

List of Figures
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ReNeuron Group Plc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[ReNeuron Group Plc (RENE):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Fuji Pharma Co Ltd (4554):企業の財務・戦略的SWOT分析
    Summary Fuji Pharma Co Ltd (Fuji Pharma) develops, manufactures, and commercializes pharmaceutical products. The company specializes in offering injection agents, drugs for external use, internal drugs, and diagnostic products among others. It also provides medical care products for women, acute med …
  • MicroTransponder Inc:医療機器:M&Aディール及び事業提携情報
    Summary MicroTransponder Inc (MicroTransponder) is a medical device company that develops paired vagus nerve stimulation systems. The company provides paired VNS system which is used in two clinical trials for treating tinnitus and upper limb mobility issues for stroke patients. It also develops SAI …
  • Banca Monte dei Paschi di Siena S.p.A.:戦略・SWOT・企業財務分析
    Banca Monte dei Paschi di Siena S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Banca Monte dei Paschi di Siena S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Ubisoft Entertainment SA (UBI):企業の財務・戦略的SWOT分析
    Ubisoft Entertainment SA (UBI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Delaware Municipal Electric Corporation, Inc.:企業の戦略的SWOT分析
    Delaware Municipal Electric Corporation, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors …
  • Tupperware Brands Corporation:企業の戦略・SWOT・財務分析
    Tupperware Brands Corporation - Strategy, SWOT and Corporate Finance Report Summary Tupperware Brands Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Penn Virginia Corporation (PVAC):石油・ガス:M&Aディール及び事業提携情報
    Summary Penn Virginia Corp (Penn Virginia) is an independent oil and gas company. It explores, develops, and produces crude oil, Natural gas liquids (NGL), and natural gas. The company’s operations consist primarily of drilling unconventional horizontal development wells and operating producing well …
  • ORBIT Communication Systems Ltd:企業の戦略・SWOT・財務情報
    ORBIT Communication Systems Ltd - Strategy, SWOT and Corporate Finance Report Summary ORBIT Communication Systems Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Tullow Oil Plc (TLW):石油・ガス:M&Aディール及び事業提携情報
    Summary Tullow Oil Plc (Tullow) is an independent upstream oil and gas company. It explores for, develops and produces oil and natural gas in Africa and South America. The company has licenses, both onshore and offshore, across Africa, and offshore exploration licenses in Guyana, Suriname, Uruguay, …
  • Medikit Co Ltd (7749):企業の財務・戦略的SWOT分析
    Summary Medikit Co Ltd (Medikit) is a medical equipment provider that offers vascular devices. The company offers IV catheter, hemodialysis and intervention products. Its products include supercath Z3V, supercath 5 safety IV catheter, supercath AZ, supercath CLS, i-works, seiha, parent plus, parent …
  • Aspyrian Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Aspyrian Therapeutics Inc (Aspyrian Therapeutics) is a clinical stage biotechnology company that develops first-in-class precision targeted cancer drugs for the treatment of solid tumors. The company harnesses the Photoimmunotherapy (PIT) platform to develop its products. Its lead pipeline p …
  • JBS S.A.:企業のM&A・事業提携・投資動向
    JBS S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's JBS S.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • Albumedix AS-製薬・医療分野:企業M&A・提携分析
    Summary Albumedix A/S (Albumedix), a subsidiary of Novozymes A/S, is a developer of albumin-based products and technologies for advanced drug and vaccine formulation, extended drug half-life and improved drug delivery. Its product Recombumin is a recombinant human albumin used in the manufacture of …
  • Empresas Publicas De Medellin ESP:電力:M&Aディール及び事業提携情報
    Summary Empresas Publicas De Medellin ESP (EPM) is a decentralized body, operational under the ownership of Medellin municipality. It generates, transmits, and distributes electricity as well as undertakes gas distribution, wastewater and garbage treatment, and telecommunications services across the …
  • Siemens Healthcare GmbH:医療機器:M&Aディール及び事業提携情報
    Summary Siemens Healthcare GmbH d/b/a Siemens Healthineers, a subsidiary of Siemens AG, is a global medical device company that designs, develops, manufactures and distributes medical devices and technologies for diagnostic markets. Its major products include healthcare IT, laboratory diagnostics eq …
  • BGR Energy Systems Ltd:企業の戦略・SWOT・財務情報
    BGR Energy Systems Ltd - Strategy, SWOT and Corporate Finance Report Summary BGR Energy Systems Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Montefiore Medical Center-製薬・医療分野:企業M&A・提携分析
    Summary Montefiore Medical Center (MMC) is a healthcare service provider that offers clinical services. The center offers services such as allergy and immunology, orthopaedics, dentistry and oral surgery, dermatology, endocrinology, digestive and liver diseases, neurological surgery, otorhinolaryngo …
  • Kane Biotech Inc (KNE):医療機器:M&Aディール及び事業提携情報
    Summary Kane Biotech Inc (Kane Biotech) is a developer of pharmaceutical products that prevent and remove microbial biofilms. The company uses patent protected technology based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. It develop …
  • Aminex PLC (AEX):企業の財務・戦略的SWOT分析
    Summary Aminex PLC (Aminex) is an oil and gas company that explores, develops and produces oil and gas reserves in Africa. The company provides assets such as Valeni field and Viktorovka field in Moldova; West Esh el Mellaha-2 in Egypt; and Kiliwani North development, Nyuni exploration, and Ruvuma e …
  • Mermaid Maritime Public Co Ltd (DU4):石油・ガス:M&Aディール及び事業提携情報
    Summary Mermaid Maritime Public Co Ltd (Mermaid Maritime), a subsidiary of Thoresen Thai Agencies PCL, is a subsea and drilling service provider. The company’s business includes mermaid subsea and mermaid drilling. It provides diving equipment, remotely operated vehicles and drilling and accommodati …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆